CY1106560T1 - Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων - Google Patents

Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων

Info

Publication number
CY1106560T1
CY1106560T1 CY20071100590T CY071100590T CY1106560T1 CY 1106560 T1 CY1106560 T1 CY 1106560T1 CY 20071100590 T CY20071100590 T CY 20071100590T CY 071100590 T CY071100590 T CY 071100590T CY 1106560 T1 CY1106560 T1 CY 1106560T1
Authority
CY
Cyprus
Prior art keywords
adenosine receptor
making
methods
receptor antagonists
disorders
Prior art date
Application number
CY20071100590T
Other languages
English (en)
Inventor
James E. Dowling
Carol L. Ensinger
Gnanasambandam Kumaravel
Russell C. Petter
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1106560T1 publication Critical patent/CY1106560T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η εφεύρεση βασίζεται στην ανακάλυψη ότι ενώσεις του Τύπου (I) είναι απροσδόκητα εντόνως ισχυροί και εκλεκτικοί αναστολείς του υποδοχέα Α1 αδενοσίνης. Ανταγωνιστές Α1 αδενοσίνης μπορεί να είναι χρήσιμοι στη πρόληψη και θεραπεία πολυάριθμων ασθενειών, που συμπεριλαμβάνουν καρδιακές και κυκλοφορικές διαταραχές, εκφυλιστικές διαταραχές του κεντρικού νευρικού συστήματος, αναπνευστικές διαταραχές και πολλές ασθένειες για τις οποίες είναι κατάλληλη διουρητική θεραπευτική αγωγή. Σε μία πραγματοποίηση, η εφεύρεση χαρακτηρίζει μία ένωση του Τύπου (I) όπου το R3 επιλέγεται από συγκεκριμένες δικυκλοεπτύλ, δικυκλοοκτύλ, τρικυκλοεπτύλ και τρικυκλοοκτύλ ομάδες.
CY20071100590T 1999-11-12 2007-05-04 Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων CY1106560T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (1)

Publication Number Publication Date
CY1106560T1 true CY1106560T1 (el) 2012-01-25

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100590T CY1106560T1 (el) 1999-11-12 2007-05-04 Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων

Country Status (33)

Country Link
US (4) US6605600B1 (el)
EP (2) EP1230241B1 (el)
JP (1) JP2003513976A (el)
KR (1) KR100845488B1 (el)
CN (1) CN1187354C (el)
AT (1) ATE353328T1 (el)
AU (1) AU784528B2 (el)
BG (1) BG106693A (el)
BR (1) BR0015540A (el)
CA (1) CA2390590C (el)
CY (1) CY1106560T1 (el)
CZ (1) CZ20021615A3 (el)
DE (1) DE60033310T2 (el)
DK (1) DK1230241T3 (el)
EA (1) EA010260B1 (el)
EE (1) EE200200248A (el)
ES (1) ES2281367T3 (el)
GE (1) GEP20043267B (el)
HK (1) HK1049153B (el)
HU (1) HUP0203371A3 (el)
IL (1) IL149486A0 (el)
IS (1) IS6380A (el)
MX (1) MXPA02004795A (el)
NO (1) NO20022237L (el)
NZ (2) NZ519427A (el)
PL (1) PL198156B1 (el)
PT (1) PT1230241E (el)
SK (1) SK6622002A3 (el)
TR (1) TR200301062T2 (el)
UA (1) UA77937C2 (el)
WO (1) WO2001034604A2 (el)
YU (1) YU33702A (el)
ZA (1) ZA200203702B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DK1230241T3 (da) * 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
BR0312137A (pt) * 2002-06-12 2005-04-05 Mcw Res Found Inc Processo de tratamento de dano de reperfusão de isquemia usando antagonistas de receptor de adenosina
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
US7579331B2 (en) 2003-04-25 2009-08-25 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
MY147661A (en) 2006-05-19 2012-12-31 Abbott Lab Fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2028235C (en) 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
CA2082325A1 (en) 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
EP0556778A3 (en) 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (el) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057645A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'oedeme hepatique
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
EP1092435B1 (en) 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
DK1230241T3 (da) * 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2001034604A3 (en) 2002-01-10
DK1230241T3 (da) 2007-06-04
UA77937C2 (en) 2007-02-15
CN1187354C (zh) 2005-02-02
EP1775297A3 (en) 2008-12-03
PT1230241E (pt) 2007-05-31
EA200200562A1 (ru) 2002-10-31
ATE353328T1 (de) 2007-02-15
SK6622002A3 (en) 2003-02-04
PL356044A1 (en) 2004-06-14
PL198156B1 (pl) 2008-05-30
MXPA02004795A (es) 2005-07-01
EP1230241A2 (en) 2002-08-14
CA2390590A1 (en) 2001-05-17
US20050222179A1 (en) 2005-10-06
KR100845488B1 (ko) 2008-07-10
WO2001034604A2 (en) 2001-05-17
EP1230241B1 (en) 2007-02-07
ES2281367T3 (es) 2007-10-01
NZ527918A (en) 2005-05-27
HUP0203371A2 (hu) 2003-02-28
US6605600B1 (en) 2003-08-12
CZ20021615A3 (cs) 2002-08-14
JP2003513976A (ja) 2003-04-15
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
NO20022237L (no) 2002-07-12
HK1049153A1 (en) 2003-05-02
GEP20043267B (en) 2004-06-25
US20080004293A1 (en) 2008-01-03
YU33702A (sh) 2005-03-15
EP1775297A2 (en) 2007-04-18
IS6380A (is) 2002-05-10
BR0015540A (pt) 2002-07-23
AU2042101A (en) 2001-06-06
BG106693A (bg) 2003-01-31
EE200200248A (et) 2003-06-16
US20030225038A1 (en) 2003-12-04
EA010260B1 (ru) 2008-06-30
CA2390590C (en) 2010-03-16
AU784528B2 (en) 2006-04-27
HK1049153B (zh) 2007-09-28
NZ519427A (en) 2003-08-29
DE60033310D1 (de) 2007-03-22
CN1399636A (zh) 2003-02-26
ZA200203702B (en) 2003-10-29
IL149486A0 (en) 2002-11-10
HUP0203371A3 (en) 2005-02-28
DE60033310T2 (de) 2007-11-22
KR20020049043A (ko) 2002-06-24

Similar Documents

Publication Publication Date Title
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
DK1230243T3 (da) Polycycloalkylpuriner som adenosinreceptorantagonister
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
DK1096936T3 (da) Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister
TR200001970T2 (tr) MSS bozukluklarının tedavisine mahsus triazin bileşikleri.
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
ES2144888T3 (es) 4-(6-fluoro-(1h)-indol-3-il)-1,2,3,6-tetrahidropiridina sustituida para el tratamiento de desordenes del snc.
NO20053612D0 (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet